Biosimilar drugs Archives - CDR

Cardinal Health predicts 2022 to be turning point for biosimilars in the U.S.

February 7, 2022 by Chain Drug Review 2022 Biosimilar Report: The U.S. Journey and Path Forward, Biosimilar drugs, Cardinal Health Leading Headlines, Pharmacy

DUBLIN, Ohio — Cardinal Health has published its 2022 Biosimilars Report: The U.S. Journey and Path Ahead, a publication that brings together the latest industry data on biosimilar utilization and payer coverage with survey data from health care providers, and views from leading physicians and experts on biosimilars. The report delivers robust data and insights

Biosimilars could generate $38.4 billion in savings over five years

January 10, 2022 by Chain Drug Review Biosimilar drugs, RAND Corp. Leading Headlines, Pharmacy

NEW YORK — Biosimilar drugs could drive down prices for expensive medicines used to treat illnesses such as cancer and rheumatoid arthritis, with savings estimated to be $38.4 billion or 5.9% of projected total U.S. spending on biologics from 2021 to 2025, according to a new RAND Corporation study. More aggressive biosimilar uptake and competition